Key result
Intraperitoneal flecainide successfully converted supraventricular tachycardia in a hydropic fetus that was initially refractory to transplacental treatment.
Why the study?
Supraventricular tachycardia is the most common fetal tachyarrhythmia and if persistent is often associated with fetal hydrops, which can cause intrauterine and neonatal death.
Does intraperitoneal flecainide convert refractory supraventricular tachycardia in a hydropic fetus?
Comparison
Transplacental treatment supplemented with intraperitoneal flecainide
Design
Case report
Authors
Loading...
Hypothesis-generating for intraperitoneal flecainide in refractory fetal SVT with hydrops; larger prospective studies needed before adoption.
Case Report (n=1)
Does intraperitoneal flecainide convert refractory supraventricular tachycardia in a hydropic fetus?
Intraperitoneal flecainide may be an effective rescue therapy for fetal supraventricular tachycardia with hydrops refractory to transplacental treatment.
Vedel et al. (2020) conducted a case report in Fetal supraventricular tachycardia with hydrops (n=1). Intraperitoneal flecainide was evaluated on Conversion of supraventricular tachycardia. Intraperitoneal flecainide successfully converted supraventricular tachycardia in a hydropic fetus that was initially refractory to transplacental treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: